ArticleScientific reports2021
Cytotoxic T-lymphocyte elicited vaccine against SARS-CoV-2 employing immunoinformatics framework.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Designing a Vaccine for the Monkeypox Virus Using Immunoinformatics and Structural Tools.Advanced biomedical research · 2026Article
- Harnessing computational immunology to design targeted subunit vaccines for infectious bursal disease in poultry.Frontiers in bioinformatics · 2025Article
- Assessing acute kidney injury risk after COVID vaccination and infection in a large cohort study.NPJ vaccines · 2024Article
- Otitis Media with ANCA-Associated Vasculitis Following COVID-19 mRNA Vaccination: A Case Report.The American journal of case reports · 2024Article
- Epitope-based therapeutic targets in HCV genotype 1 non-structural proteins: a novel strategy to combat emerging drug resistance.Frontiers in cellular and infection microbiology · 2024Article
- ANCA Associated Glomerulonephritis Following SARS-CoV-2 Vaccination: A Case Series and Systematic Review.Vaccines · 2023Review
- In silico formulation of a next-generation multiepitope vaccine for use as a prophylactic candidate against Crimean-Congo hemorrhagic fever.BMC medicine · 2023Article
- Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to?Vaccines · 2023Review
- Mapping Potential Vaccine Candidates Predicted by VaxiJen for Different Viral Pathogens between 2017-2021-A Scoping Review.Vaccines · 2022Article
- Renal Side Effects of COVID-19 Vaccination.Vaccines · 2022Review
- Traditional Chinese medicine treatment for COVID-19: An overview of systematic reviews and meta-analyses.Journal of integrative medicine · 2022Review
- In Silico Studies on Zinc Oxide Based Nanostructured Oil Carriers with Seed Extracts ofMolecules (Basel, Switzerland) · 2022Article
- Molecular dynamics simulation approach for discovering potential inhibitors against SARS-CoV-2: A structural review.Journal of molecular liquids · 2022Review
- New-Onset Acute Kidney Disease Post COVID-19 Vaccination.Vaccines · 2022Review
- Designing a multi-epitope vaccine against coxsackievirus B based on immunoinformatics approaches.Frontiers in immunology · 2022Article
- Coexistence of Pemphigus Vulgaris and Lichen Planus following COVID-19 Vaccination.Case reports in dermatological medicine · 2022Article
- Immunoinformatic-based design of immune-boosting multiepitope subunit vaccines against monkeypox virus and validation through molecular dynamics and immune simulation.Frontiers in immunology · 2022Article
- Evaluation of the consistence between the results of immunoinformatics predictions and real-world animal experiments of a new tuberculosis vaccine MP3RT.Frontiers in cellular and infection microbiology · 2022Article
- Immunoinformatics design of B and T-cell epitope-based SARS-CoV-2 peptide vaccination.Frontiers in immunology · 2022Article
- Target-based drug discovery, ADMET profiling and bioactivity studies of antibiotics as potential inhibitors of SARS-CoV-2 main protease (MVirusdisease · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of effective counteragents against the novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains, requires clear insights and information for understanding the immune responses associated with it. This global pandemic has pushed the healthcare system and restricted the movement of people and succumbing of the available therapeutics utterly warrants the development of a potential vaccine to contest the deadly situation. In the present study, highly efficacious, immunodominant cytotoxic T-lymphocyte (CTL) epitopes were predicted by advanced immunoinformatics assays using the spike glycoprotein of SARS-CoV2, generating a robust and specific immune response with convincing immunological parameters (Antigenicity, TAP affinity, MHC binder) engendering an efficient viral vaccine. The molecular docking studies show strong binding of the CTL construct with MHC-1 and host membrane specific TLR2 receptors. The molecular dynamics simulation in an explicit system confirmed the stable and robust binding of CTL epitope with TLR2. Steep magnitude RMSD variation and compelling residual fluctuations existed in terminal residues and various loops of the β linker segments of TLR2-epitope (residues 105-156 and 239-254) to about 0.4 nm. The reduced R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.